Lifespan Vision Ventures Takes the Lead in Remedium Bio's $10 Million Series A Financing Round
On August 10, 2026, Lifespan Vision Ventures announced its leadership in a $10 million Series A financing round for Remedium Bio, Inc. This strategic investment is set to propel the innovative biotech company into its first-in-human clinical development phase. With additional participation from significant players like Eli Lilly and Company and HKX Capital, the financing represents a crucial step in advancing Remedium's groundbreaking platform aimed at developing durable protein therapeutics.
Remedium Bio has pioneered a unique approach that utilizes adipocytes as a durable site for the production of therapeutic proteins. This innovation allows for controlled and long-lasting expression of these proteins through minimally invasive subcutaneous administration. By leveraging its advanced therapeutics, the company aims to provide patients suffering from chronic diseases with a sustainable solution, enhancing the effectiveness of their treatment over an extended period. The funding will enable the company to push forward with its lead programs, broaden its therapeutic platform, and prepare for clinical trial launches.
The lead and founding partner at Lifespan Vision Ventures, Andrew Worden, expressed great optimism regarding Remedium's groundbreaking platform, noting that it addresses critical limitations often encountered in chronic biologic therapy. He emphasized the firm belief that durable therapies, as envisioned by Remedium, will significantly enhance the treatment landscape for chronic diseases. "Remedium has built a differentiating platform, and we're proud to advocate this Series A funding to help them further their objectives," stated Worden.
Furthermore, Frank Luppino, CEO of Remedium Bio, expressed gratitude for Lifespan's involvement and highlighted the shared vision between the two organizations. With Lifespan leading this financing round, Luppino welcomed Harry Robb from Lifespan Vision Ventures to Remedium's Board of Directors, marking an essential collaboration that aims to optimize therapeutic potential toward clinical reality.
This funding round comes on the heels of several strategic collaborations and noteworthy progress across Remedium's pipeline, including preclinical studies. The investment is expected to facilitate critical advancements that demonstrate the extensive capabilities of Remedium's platform in treating cardiometabolic and other chronic diseases.
Lifespan Vision Ventures, known for its support of early-stage biotechnology focused on combating age-related diseases, sees this investment as an opportunity to back visionary founders advancing life-enhancing technologies. They specialize in solutions that promote healthy aging and increase healthspan, aligning perfectly with Remedium's mission to revolutionize gene therapy and therapeutic protein delivery.
In summary, Lifespan Vision Ventures’ leadership in Remedium Bio's Series A financing not only signifies a substantial financial commitment but also reinforces a partnership poised to foster innovation in the biotech industry. The sustainable therapeutic options on the horizon could reshape the treatment of chronic diseases, providing hope for many patients seeking advanced care options.
As Remedium Bio progresses toward clinical studies, the global health community is keenly watching, anticipating significant developments that may soon redefine therapeutic approaches across a spectrum of chronic conditions.
Remedium Bio has pioneered a unique approach that utilizes adipocytes as a durable site for the production of therapeutic proteins. This innovation allows for controlled and long-lasting expression of these proteins through minimally invasive subcutaneous administration. By leveraging its advanced therapeutics, the company aims to provide patients suffering from chronic diseases with a sustainable solution, enhancing the effectiveness of their treatment over an extended period. The funding will enable the company to push forward with its lead programs, broaden its therapeutic platform, and prepare for clinical trial launches.
The lead and founding partner at Lifespan Vision Ventures, Andrew Worden, expressed great optimism regarding Remedium's groundbreaking platform, noting that it addresses critical limitations often encountered in chronic biologic therapy. He emphasized the firm belief that durable therapies, as envisioned by Remedium, will significantly enhance the treatment landscape for chronic diseases. "Remedium has built a differentiating platform, and we're proud to advocate this Series A funding to help them further their objectives," stated Worden.
Furthermore, Frank Luppino, CEO of Remedium Bio, expressed gratitude for Lifespan's involvement and highlighted the shared vision between the two organizations. With Lifespan leading this financing round, Luppino welcomed Harry Robb from Lifespan Vision Ventures to Remedium's Board of Directors, marking an essential collaboration that aims to optimize therapeutic potential toward clinical reality.
This funding round comes on the heels of several strategic collaborations and noteworthy progress across Remedium's pipeline, including preclinical studies. The investment is expected to facilitate critical advancements that demonstrate the extensive capabilities of Remedium's platform in treating cardiometabolic and other chronic diseases.
Lifespan Vision Ventures, known for its support of early-stage biotechnology focused on combating age-related diseases, sees this investment as an opportunity to back visionary founders advancing life-enhancing technologies. They specialize in solutions that promote healthy aging and increase healthspan, aligning perfectly with Remedium's mission to revolutionize gene therapy and therapeutic protein delivery.
In summary, Lifespan Vision Ventures’ leadership in Remedium Bio's Series A financing not only signifies a substantial financial commitment but also reinforces a partnership poised to foster innovation in the biotech industry. The sustainable therapeutic options on the horizon could reshape the treatment of chronic diseases, providing hope for many patients seeking advanced care options.
As Remedium Bio progresses toward clinical studies, the global health community is keenly watching, anticipating significant developments that may soon redefine therapeutic approaches across a spectrum of chronic conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.